Abstract
Advances in understanding the pathophysiology of Alzheimer disease (AD), together with a US national plan to discover interventions to prevent AD by 2025, have led to clinical trials examining treatment in people at risk for development of the disease before they have disabling cognitive impairments.1 These trials enroll cognitively normal persons with evidence of AD biomarkers, including amyloid as measured by positron emission tomography (PET) or cerebrospinal fluid, often necessitating biomarker disclosure to participants.2 The amyloid imaging appropriate use criteria suggest that clinical disclosure is appropriate to aid the diagnosis of persons with dementia or mild cognitive impairment. However, the criteria do not recommend disclosure to cognitively normal adults,3 explaining that therapy for this group would change this recommendation. This explanation signals how biomarker disclosure to cognitively normal adults will be translated into clinical practice. There is no consensus, however, about whether and how to return AD biomarker results to cognitively normal adults given the prognostic uncertainty and absence of available treatments.4-7

This publication has 17 references indexed in Scilit: